Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:30:15 2024-05-17 am EDT			5-day change	1st Jan Change
2.95 ^USD	+1.37%		+1.39%	-25.00%

May. 08	Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	CI
Apr. 18	Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	CI

ITUS Corporation Appoints Lew Titterton to its Board of Directors

July 18, 2017 at 06:30 pm EDT

ITUS Corporation announced that Lew Titterton has been appointed to its Board of Directors. Mr. Titterton rejoins the ITUS Board of Directors after having previously served as a Director from August 2010 through August 2016, the last four years of which as Chairman of the Board.

Latest news about Anixa Biosciences, Inc.

Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	May. 08	CI
Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	Apr. 18	CI
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 12	CI
Anixa Biosciences Initiates Higher Dosing in Phase 1 Study of Ovarian Cancer Treatment	Feb. 12	MT
Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology	Jan. 23	MT
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology	Jan. 23	CI
North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	Jan. 23	DJ
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Jan. 16	CI
North American Morning Briefing : Stock Futures -2-	Jan. 16	DJ
North American Morning Briefing : Samsung Warning Knocks Tech Stocks	Jan. 09	DJ
North American Morning Briefing : Stock Futures Struggle After Weak China Data	Jan. 02	DJ
Anixa Biosciences Unveils 'Positive' Results From Phase 1 Trial of Breast Cancer Vaccine	Dec. 07	MT
Transcript : Anixa Biosciences, Inc. - Special Call	Dec. 06
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine	Dec. 06	CI
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology	Nov. 27	CI
Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board	23-10-23	CI
Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial	23-10-13	CI
Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board	23-09-19	CI
Anixa Biosciences, Inc.(NasdaqCM:ANIX) added to S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : Concerns About -2-	23-09-07	DJ
Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-06	CI
Anixa Biosciences Starts Treatment of Third Patient in Clinical Trial of Ovarian Cancer Therapy; Shares Rise	23-08-28	MT
Anixa Biosciences Says Cleveland Clinic Enrolling Patients for Study of Cancer Vaccine Plus Keytruda	23-08-07	MT
Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial	23-08-07	CI
Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology	23-07-27	CI

Chart Anixa Biosciences, Inc.

Duration

Period

More charts

Company Profile

Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Companyâs vaccine portfolio consists of technology focused on the immunization against specific retired proteins.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.91 USD

Average target price

12 USD

Spread / Average Target

+312.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANIXA BIOSCIENCES, INC.	-25.00%	92.83M
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+49.28%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research